



Altea Therapeutics


***Replacing Needle Injections for
Biotechnology Drugs and Vaccines
with a Convenient Skin Patch***

Why Transdermal Patches


Steady drug levels
Improved compliance
Stop dosing immediately

Patient control





1. Microseconds pulse of electrical energy across filament film
2. Center of filament heats rapidly and ablates stratum corneum
3. Aqueous microchannels provide portal for drug delivery



Product Portfolio


- **Diabetes**
- **Pain**
- **Thromboses**
- **Osteoporosis**
- **Psychoses**

Collaborations

- **Teikoku Seiyaku (Japan)**
- **Pharma for low molecular weight heparins**
- **Pharma for undisclosed proteins**

Venture Funds (series C)

- **Domain, Venrock, Merrill Lynch, KBC Investco, Aperture, vSpring, Quilvest**



Currently employ 75 staff and contractors
More than 50% staff with diverse backgrounds
recruited from outside of Georgia

Pharmaceutical Sciences

Engineering

Clinic personnel

Clinical manufacturing

Quality Infrastructure

Raised \$60 M venture capital in last 5 years

Anchor tenant of Technology Enterprise Park

Recipient of \$2 M from Georgia Life Sciences Facility
Fund

\$350-\$450 M required to bring products to market
during next 5 years

Potential for significant growth in employee base

Bio Paradigm

Action by Georgians

Invest

Turn Away

**Major Impact
on Economy
and Welfare for
Georgians**

**000s H-P Jobs
Product Trove
Gains in
Infrastructure**

**Lost Opportunity
Georgia Becomes
a Bio Backwater**

**Minor Impact
on Economy
and Welfare for
Georgians**

**Investment
Wasted**

Status quo